Novo Nordisk
-
Gilead and Novo Nordisk advance NASH collaboration to larger clinical study
Clinical tests of drugs from Gilead Sciences and Novo Nordisk have yielded encouraging results in nonalcoholic steatohepatitis (NASH), and the partners now want to see if the drug combinations help patients in a larger mid-stage study. The planned Phase 2b study expands on a 2019 R&D alliance.
-
In fight over drug discounts, HHS lawyer sides with hospitals
Prominent drug companies have said they want to curb waste and abuse in the 340B Drug Pricing Program. But the top lawyer at HHS is echoing the criticism hospitals have been leveling against the drug companies over access to the program.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Hospitals sue drug companies over discount program
The lawsuit follows action by at least a half-dozen drug companies to rein in what they see as waste and abuse in the program, overseen by the Department of Health and Human Services. Meanwhile, the Hospital plaintiffs have a potentially powerful ally in the person picked to head the department under the incoming Biden administration.
-
Lava Therapeutics raises $83M in Series C round for bispecific antibodies
The company plans to start clinical development next year. Its focus is on bispecific antibodies – a form of cancer immunotherapy – that use gamma-delta “surveillance” T cells.
-
Insurers will limit insulin costs to $35 copay for Medicare Part D plans next year
More than 1,750 Medicare part D plans and Medicare Advantage plans will limit out-of-pocket insulin costs to a $35 copay next year. The change would make patients’ out-of-pocket costs more consistent than the current system, where payments fluctuate in different stages of their Part D plan.
-
Amid high insulin prices, many patients turn to unregulated sales on Craigslist, study shows
While many sellers were found to express altruistic motives, the researchers wrote that improperly stored insulin creates risks of lost potency and contamination. The findings highlight the need for substantive policy reform, according to the study’s lead author.
-
Novo Nordisk, bluebird bio partner on genome editing in hemophilia
The companies will use Novo Nordisk’s experience with hemophilia and bluebird’s TALENs-based genome editing technology, megaTAL, with a particular focus on hemophilia A.
-
FDA approves Novo Nordisk’s oral Type 2 diabetes drug
The drug, Rybelsus, is the first oral medication in the GLP-1 receptor agonist class. The approval was based on data from 10 trials that enrolled more than 9,500 patients.
-
Taiwanese startup Health2Sync inks Novo Nordisk deal to drive growth in Japan
Through the deal Health2Sync will work with Novo Nordisk to market and localize the company’s patient management tool and SyncHealth app, which nudges users towards timely healthy behaviors around exercise, diet and blood glucose management.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
Lilly’s lower-cost insulin Humalog still too expensive, senator says
Sen. Dick Durbin, D-Illinois, was also among four signatories to a letter to FDA Commissioner Scott Gottlieb calling on the agency to speed up approvals of generic versions of insulin products.
-
Therachon raises $60 million in mezzanine financing for rare disease drugs
The Basel, Switzerland-based biotech company plans to trial the drug in achondroplasia patients next year.
-
Glooko’s out-of-sync moment with Novo Nordisk on its smart insulin pen project
Interviews with Glooko’s previous CEO, new CEO and a Novo Nordisk executive show that the two company’s messaging around the development of a smart insulin pen is not aligned.
-
A look at how one pharma company responded to the pressure on drug prices: Ramping up political activity
The pharma industry as a whole has cranked up political contributions and lobbying. Meanwhile, despite much talk about change, Congress and the Trump administration have done little to control drug prices or threaten drug-company profits.
-
Novo Nordisk collaborates with healthcare startup to incentivize diabetes medication adherence
The medication adherence collaboration with Novo Nordisk and Sempre Health will focus on incentivizing diabetes patients.
-
States investigate pharma companies, CVS Health as diabetes drug prices reach record highs
The United States is one of the few developed countries without regulations on prescription drug pricing.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
